Search

Your search keyword '"Suga, Takayoshi"' showing total 15 results
Start Over Author "Suga, Takayoshi" Search Limiters Peer Reviewed Publication Year Range Last 10 years
15 results on '"Suga, Takayoshi"'

5. P16-2 A retrospective analysis of pembrolizumab in patients with high microsatellite instability cholangiocarcinoma

Author

Shimizu, Takehiro, primary, Naganuma, Atsushi, additional, Matsui, Ayako, additional, Murakami, Tatsuma, additional, Kanamaya, Yuuki, additional, Zennyoji, Dan, additional, Suga, Takayoshi, additional, Tojima, Hiroki, additional, Yamazaki, Yuichi, additional, Kakizaki, Satoru, additional, Sato, Ken, additional, and Uraoka, Toshio, additional

Published
2022
Full Text
View/download PDF

7. Disordered branched chain amino acid catabolism in pancreatic islets is associated with postprandial hypersecretion of glucagon in diabetic mice

Author

Wada, Eri, primary, Kobayashi, Masaki, additional, Kohno, Daisuke, additional, Kikuchi, Osamu, additional, Suga, Takayoshi, additional, Matsui, Sho, additional, Yokota-Hashimoto, Hiromi, additional, Honzawa, Norikiyo, additional, Ikeuchi, Yuichi, additional, Tsuneoka, Haruka, additional, Hirano, Touko, additional, Obinata, Hideru, additional, Sasaki, Tsutomu, additional, and Kitamura, Tadahiro, additional

Published
2021
Full Text
View/download PDF

8. The first reported case of Noonan syndrome complicated with hepatocellular carcinoma

Author

Kakizaki, Satoru, primary, Uehara, Daisuke, additional, Tojima, Hiroki, additional, Suga, Takayoshi, additional, Yamazaki, Yuichi, additional, Sato, Ken, additional, Kubo, Norio, additional, Shirabe, Ken, additional, Yokota, Takayuki, additional, Shibuya, Kei, additional, Maehara, Tatsurou, additional, Yokoo, Hideaki, additional, Naganuma, Atsushi, additional, and Uraoka, Toshio, additional

Published
2021
Full Text
View/download PDF

10. Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain

Author

Yamazaki, Yuichi, primary, Uehara, Daisuke, additional, Kanayama, Yuki, additional, Suga, Takayoshi, additional, Ueno, Takashi, additional, Hatanaka, Takeshi, additional, Takakusagi, Satoshi, additional, Tojima, Hiroki, additional, Takizawa, Daichi, additional, Naganuma, Atsushi, additional, Kosone, Takashi, additional, Nakajima, Hiroaki, additional, Sato, Ken, additional, Kakizaki, Satoru, additional, Takagi, Hitoshi, additional, Uraoka, Toshio, additional, Takahashi, Masaharu, additional, Nagashima, Shigeo, additional, and Okamoto, Hiroaki, additional

Published
2020
Full Text
View/download PDF

11. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling

Author

Suga, Takayoshi, primary, Sato, Ken, additional, Ohyama, Tatsuya, additional, Matsui, Sho, additional, Kobayashi, Takeshi, additional, Tojima, Hiroki, additional, Horiguchi, Norio, additional, Yamazaki, Yuichi, additional, Kakizaki, Satoru, additional, Nishikido, Ayaka, additional, Okamura, Takashi, additional, Yamada, Masanobu, additional, Kitamura, Tadahiro, additional, and Uraoka, Toshio, additional

Published
2020
Full Text
View/download PDF

15. [Liver injury in patients with moderate II COVID-19 who received dexamethasone monotherapy].

Author

Yamazaki Y, Kanayama Y, Uehara D, Suga T, Tanaka H, Tojima H, Kuribayashi S, Sato K, Kakizaki S, and Uraoka T

Subjects
Dexamethasone adverse effects, Humans, Liver, Male, COVID-19 complications, Respiratory Insufficiency, COVID-19 Drug Treatment
Abstract

We examined 171 patients with novel coronavirus disease 2019 (COVID-19) with liver injury in the respiratory failure groups and the nonrespiratory failure groups and investigated 41 patients with moderate II COVID-19 with respiratory failure who received dexamethasone (Dex) monotherapy in the liver injury group and the nonliver injury group at the time before treatment. The respiratory failure group had 64% more liver damage than the nonrespiratory failure group, was older, had more men, and had significantly more complications from lifestyle-related diseases such as hypertension and diabetes. Obesity was more common in the liver injury group prior to Dex monotherapy, and the liver CT value was significantly lower than in the nonliver injury group. Liver injury worsened in 41% of patients after Dex monotherapy, but there was no significant difference in the frequency before Dex monotherapy between the liver injury group and the nonliver injury group, and the degree of liver injury was mild in all cases, improving in 38% of the liver injury group. Dex monotherapy was a safe treatment for moderate II COVID-19, which frequently resulted in liver injury.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results